TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02476890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 100 mg
Description: Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 100 mg
Description: Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 100 mg
Description: Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 100 mg
Description: Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
Study: NCT02135172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Study: NCT02572024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: Baroreflex activation therapy device ON

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baroreflex activation therapy device OFF
Study: NCT02606409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol sedation at a starting dose of 10-70 µg/kg/hour.
Study: NCT01301469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.42 in plasma adapted Ringer's solution
Description: 60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% HES 130/0.4 in a saline solution
Description: 60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
Study: NCT05561036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome doxorubicin
Description: Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline solution
Study: NCT02275325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative vestibular rehabilitation
Description: 12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
Study: NCT02914522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily
Study: NCT02537522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 8.5 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 8.5 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 8.5 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 8.5 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 9.0 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 9.0 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 9.0 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 9.0 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
Study: NCT02533713

Intervention type: DEVICE
Group type: OTHER
Intervention: Exoskeleton assisted gait training
Description: Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton assisted gait training
Description: Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
Study: NCT01521624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
Study: NCT03312439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Given advice
Description: Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
Study: NCT02680093

Intervention type: OTHER
Intervention: Cervical length in pregnant women.
Description: Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes.
Study: NCT00300040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoglobin glutamer 250 - bovine
Description: intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Hydroxyethylstarch
Description: 250ml for intravenous infusion
Study: NCT04329663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indonesian computer-based game prototype
Description: In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
Study: NCT03692520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
Study: NCT04352452

Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: differences in musculoskeletal and cognitive stress

Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: differences in musculoskeletal and cognitive stress
Study: NCT02729272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic colpotomy by ultrasonic ESD
Description: In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colpotomy by monopolar ESD
Description: In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar ESD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ESD
Study: NCT03649165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
Study: NCT02013466

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS A
Description: High-whey protein, leucine-rich, low-caloric ONS in powder format

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS B
Description: High casein-protein, low-caloric control product (isocaloric to product A)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS C
Description: High casein-protein, high-caloric control product.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS D
Description: high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
Study: NCT00541892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium with no human serum albumine added
Description: See above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medium
Description: See above
Study: NCT00184106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
Description: Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
Description: Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
Description: Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
Description: Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
Study: NCT02639793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
Study: NCT02833649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Implantable collamer Lens
Description: The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
Study: NCT00000271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
Study: NCT03647371

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Macintosh laryngoscopy
Description: intubation with MAcintosh laryngoscopy after anesthetic induction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: McGrath MAC video laryngoscopy
Description: intubation with McGrath MAC videolaryngoscopy after anesthetic induction
Study: NCT04686994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC 41
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC 41 Placebo
Description: Oral tablets
Study: NCT02800512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic sacrocolpopexy
Description: Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high uterosacral ligament suspension
Description: Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
Study: NCT04813172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Assessment
Description: Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit.
Study: NCT00375882

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hypothermia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cochlear implantation with mild hypothermia
Study: NCT03885739

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Pericapsular Nerve Group block
Description: Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
Study: NCT04236206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Short Message Service
Description: SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~* The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~* The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~* Patients will be encouraged to send messages/call the researcher for any queries encountered.
Study: NCT00584220

Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: alphafilcon A toric
Description: contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: alphafilcon A toric
Description: contact lens
Study: NCT04207957

Intervention type: DRUG
Group type: OTHER
Intervention: Olorofim
Description: 150 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Olorofim
Description: 150 mg
Study: NCT04329715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expedited postoperative activity instructions
Description: Ad lib postoperative activity and return to work recommendations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative activity restructions
Description: Standard conservative postoperative activity and return to work recommendations